Literature DB >> 26030479

RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.

Christopher J Rhodes1,2,3, Hogune Im2,4, Aiqin Cao1,2,3, Jan K Hennigs1,2,3, Lingli Wang1,2,3, Silin Sa1,2,3, Pin-I Chen1,2,3, Nils P Nickel1,2,3, Kazuya Miyagawa1,2,3, Rachel K Hopper1,2,3, Nancy F Tojais1,2,3, Caiyun G Li1,2,3, Mingxia Gu1,2,3, Edda Spiekerkoetter1,2,5, Zhaoying Xian1,2,3, Rui Chen2,4, Mingming Zhao2,3, Mark Kaschwich1,2,3, Patricia A Del Rosario1,2,5, Daniel Bernstein2,3, Roham T Zamanian1,2,5, Joseph C Wu2,5, Michael P Snyder2,4, Marlene Rabinovitch1,2,3.   

Abstract

RATIONALE: Pulmonary arterial hypertension is characterized by endothelial dysregulation, but global changes in gene expression have not been related to perturbations in function.
OBJECTIVES: RNA sequencing was used to discriminate changes in transcriptomes of endothelial cells cultured from lungs of patients with idiopathic pulmonary arterial hypertension versus control subjects and to assess the functional significance of major differentially expressed transcripts.
METHODS: The endothelial transcriptomes from the lungs of seven control subjects and six patients with idiopathic pulmonary arterial hypertension were analyzed. Differentially expressed genes were related to bone morphogenetic protein type 2 receptor (BMPR2) signaling. Those down-regulated were assessed for function in cultured cells and in a transgenic mouse.
MEASUREMENTS AND MAIN RESULTS: Fold differences in 10 genes were significant (P < 0.05), four increased and six decreased in patients versus control subjects. No patient was mutant for BMPR2. However, knockdown of BMPR2 by siRNA in control pulmonary arterial endothelial cells recapitulated 6 of 10 patient-related gene changes, including decreased collagen IV (COL4A1, COL4A2) and ephrinA1 (EFNA1). Reduction of BMPR2-regulated transcripts was related to decreased β-catenin. Reducing COL4A1, COL4A2, and EFNA1 by siRNA inhibited pulmonary endothelial adhesion, migration, and tube formation. In mice null for the EFNA1 receptor, EphA2, versus control animals, vascular endothelial growth factor receptor blockade and hypoxia caused more severe pulmonary hypertension, judged by elevated right ventricular systolic pressure, right ventricular hypertrophy, and loss of small arteries.
CONCLUSIONS: The novel relationship between BMPR2 dysfunction and reduced expression of endothelial COL4 and EFNA1 may underlie vulnerability to injury in pulmonary arterial hypertension.

Entities:  

Keywords:  collagen IV; ephrin; pulmonary hypertension; transcriptome; vascular endothelium

Mesh:

Substances:

Year:  2015        PMID: 26030479      PMCID: PMC4584250          DOI: 10.1164/rccm.201408-1528OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  50 in total

Review 1.  Gadd45 proteins: key players of repair-mediated DNA demethylation.

Authors:  Andrea Schäfer
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

2.  High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells.

Authors:  Bin Du; Li-Ming Ma; Mian-Bo Huang; Hui Zhou; Hui-Lin Huang; Peng Shao; Yue-Qin Chen; Liang-Hu Qu
Journal:  FEBS Lett       Date:  2010-01-12       Impact factor: 4.124

3.  HIF-1 alpha-induced up-regulation of miR-9 contributes to phenotypic modulation in pulmonary artery smooth muscle cells during hypoxia.

Authors:  Fabo Shan; Junxia Li; Qing-Yuan Huang
Journal:  J Cell Physiol       Date:  2014-10       Impact factor: 6.384

4.  Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival.

Authors:  Tero-Pekka Alastalo; Molong Li; Vinicio de Jesus Perez; David Pham; Hirofumi Sawada; Jordon K Wang; Minna Koskenvuo; Lingli Wang; Bruce A Freeman; Howard Y Chang; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2011-08-08       Impact factor: 14.808

5.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

6.  Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension.

Authors:  Maya Fujiwara; Hisato Yagi; Rumiko Matsuoka; Kaoru Akimoto; Michiko Furutani; Shin-ichiro Imamura; Ritei Uehara; Tomotaka Nakayama; Atsuyoshi Takao; Makoto Nakazawa; Tsutomu Saji
Journal:  Circ J       Date:  2008-01       Impact factor: 2.993

Review 7.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

8.  GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.

Authors:  Masaki Morishige; Shigeru Hashimoto; Eiji Ogawa; Yoshinobu Toda; Hirokazu Kotani; Mayumi Hirose; Shumei Wei; Ari Hashimoto; Atsuko Yamada; Hajime Yano; Yuichi Mazaki; Hiroshi Kodama; Yoshinori Nio; Toshiaki Manabe; Hiromi Wada; Hidenori Kobayashi; Hisataka Sabe
Journal:  Nat Cell Biol       Date:  2007-12-16       Impact factor: 28.824

9.  Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients.

Authors:  Chris Cheadle; Alan E Berger; Stephen C Mathai; Dmitry N Grigoryev; Tonya N Watkins; Yumiko Sugawara; Sangjucta Barkataki; Jinshui Fan; Meher Boorgula; Laura Hummers; Ari L Zaiman; Reda Girgis; Michael A McDevitt; Roger A Johns; Frederick Wigley; Kathleen C Barnes; Paul M Hassoun
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

10.  Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

Authors:  Dario Caccia; Francesca Miccichè; Giuliana Cassinelli; Piera Mondellini; Patrizia Casalini; Italia Bongarzone
Journal:  Mol Cancer       Date:  2010-10-18       Impact factor: 27.401

View more
  45 in total

1.  Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.

Authors:  Nancy F Tojais; Aiqin Cao; Ying-Ju Lai; Lingli Wang; Pin-I Chen; Miguel A Alejandre Alcazar; Vinicio A de Jesus Perez; Rachel K Hopper; Christopher J Rhodes; Matthew A Bill; Lynn Y Sakai; Marlene Rabinovitch
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-15       Impact factor: 8.311

2.  Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.

Authors:  Mingxia Gu; Ning-Yi Shao; Silin Sa; Dan Li; Vittavat Termglinchan; Mohamed Ameen; Ioannis Karakikes; Gustavo Sosa; Fabian Grubert; Jaecheol Lee; Aiqin Cao; Shalina Taylor; Yu Ma; Zhixin Zhao; James Chappell; Rizwan Hamid; Eric D Austin; Joseph D Gold; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch
Journal:  Cell Stem Cell       Date:  2016-12-22       Impact factor: 24.633

3.  Evolving systems biology approaches to understanding non-coding RNAs in pulmonary hypertension.

Authors:  Lloyd D Harvey; Stephen Y Chan
Journal:  J Physiol       Date:  2018-09-02       Impact factor: 5.182

4.  Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.

Authors:  Wen Tian; Xinguo Jiang; Yon K Sung; Eric Shuffle; Ting-Hsuan Wu; Peter N Kao; Allen B Tu; Peter Dorfmüller; Aiqin Cao; Lingli Wang; Gongyong Peng; Yesl Kim; Patrick Zhang; James Chappell; Shravani Pasupneti; Petra Dahms; Peter Maguire; Hassan Chaib; Roham Zamanian; Marc Peters-Golden; Michael P Snyder; Norbert F Voelkel; Marc Humbert; Marlene Rabinovitch; Mark R Nicolls
Journal:  Circulation       Date:  2019-08-29       Impact factor: 29.690

5.  Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing.

Authors:  Eric D Austin; James West; James E Loyd; Anna R Hemnes
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

Review 6.  Update in Pulmonary Vascular Disease 2015.

Authors:  Bradley A Maron; Mark T Gladwin; Marc A Simon
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

7.  Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1-Mediated Metabolic and Epigenetic Changes.

Authors:  Kazuya Miyagawa; Minyi Shi; Pin-I Chen; Jan K Hennigs; Zhixin Zhao; Mouer Wang; Caiyun G Li; Toshie Saito; Shalina Taylor; Silin Sa; Aiqin Cao; Lingli Wang; Michael P Snyder; Marlene Rabinovitch
Journal:  Circ Res       Date:  2019-01-18       Impact factor: 17.367

8.  Whole-Genome Sequencing in Common Respiratory Diseases. Ready, Set, Go!

Authors:  Craig P Hersh; Anil Vachani
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

9.  Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension.

Authors:  Pin-I Chen; Aiqin Cao; Kazuya Miyagawa; Nancy F Tojais; Jan K Hennigs; Caiyun G Li; Nathaly M Sweeney; Audrey S Inglis; Lingli Wang; Dan Li; Matthew Ye; Brian J Feldman; Marlene Rabinovitch
Journal:  JCI Insight       Date:  2017-01-26

10.  Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.

Authors:  Silin Sa; Mingxia Gu; James Chappell; Ning-Yi Shao; Mohamed Ameen; Kathryn A T Elliott; Dan Li; Fabian Grubert; Caiyun G Li; Shalina Taylor; Aiqin Cao; Yu Ma; Ryan Fong; Long Nguyen; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch
Journal:  Am J Respir Crit Care Med       Date:  2017-04-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.